ImpediMed (ASX: IPD) — Company Overview, News & Financial Data
ImpediMed specializes in bioimpedance spectroscopy devices for the diagnosis of chronic diseases like lymphedema.
ImpediMed
ImpediMed is a medical technology company that develops and commercializes non-invasive bioimpedance spectroscopy devices for fluid status and body composition monitoring. The company's core product, the SOZO Digital Health Platform, utilizes bioimpedance spectroscopy by taking measurements across 256 frequencies to differentiate intra- and extracellular fluid levels. Its application suite includes L-Dex analysis for early lymphedema detection, HF-Dex for heart failure fluid assessment, BodyComp for tissue composition analysis, and sarcopenia risk screening. ImpediMed serves clinical markets across cancer survivorship, heart health management, medical weight management, and wellness research.
Snapshot
Operations
Products and/or services of ImpediMed
- SOZO Digital Health Platform: Non-invasive bioimpedance spectroscopy system measuring 256 frequencies in a single rapid scan to separate intra- and extracellular fluid, delivering actionable patient data across cloud-connected clinical workflows at point of care.
- L-Dex Analysis for Lymphedema: FDA-cleared diagnostic application evaluating subclinical fluid accumulation to support early intervention, preventing the progression of secondary lymphedema in oncology patients, including breast cancer survivors undergoing treatment or surveillance.
- BodyComp and Segmental BodyComp Analysis: Whole-body and segmental assessment solutions measuring fluid distribution, skeletal muscle, and fat mass to monitor patient health responses during medical weight management, GLP-1 therapy, and wellness programs.
- HF-Dex Analysis for Heart Failure: Specialized fluid monitoring application providing real-time measurements of fluid accumulation to assist clinicians in tracking disease progression, optimizing diuretic therapy, and improving outpatient management of heart failure patients.
- Sarcopenia Risk Assessment: Clinical evaluation feature on the digital health platform that non-invasively analyzes muscle mass and tissue composition to identify sarcopenia risk across oncology, geriatric, and chronic illness care continuum.
- Lymphedema Prevention Program: Structured clinical program combining bioimpedance spectroscopy technology, evidence-based protocol guidelines, and patient education resources to implement routine lymphedema surveillance in oncology and survivorship care programs.
ImpediMed executive team
- Erik AndersonCEO, MD & Director
- McGregor GrantCFO & Executive Director
- Julie KuhlkenSenior Director of Marketing
- Erik JohnsonHead of Sales
- Ashley MunozDirector of Human Resources
- Gina KimballHead of Commercial Operations
- Leanne RalphCompany Secretary
Recent announcements
What ImpediMed (IPD) has told the market, newest first.
- Notice of Initial Substantial Holder
- Change of Director's Interest Notice - Mr Erik Anderson
- Change in substantial holding
- Change in substantial shareholding from AEF
- Change in substantial holding
- Change in Substantial Shareholding from AEF
- Change of Director's Interest Notice - Mr Andew Grant
- Change of Director's Interest Notice - Ms Emmanuel-Donnelly
Key financials
Reported results for ImpediMed, in AUD.
- Market cap
- 14.7M
- Revenue (TTM)
- 14.6M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- -170.4%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 14.6M | -22.1M | -24.9M | |
| 12.7M | -24.2M | -23.2M | |
| 10.3M | -19M | -19.8M | |
| 11.3M | -22.8M | -20.5M |